Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C

References

• Panel AIHG, Hepatitis C. guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C factsheet No 164; April 2014. [October 22] Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect Official Publication Eur Soc Clin Microbiol Infect Dis. 2011;17:107–115.
   PubMed Web of Science ®Google Scholar
• Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int Official J Int Assoc for the Study of the Liver. 2011;31(Suppl 2):1–3.
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:112S–21S.
   PubMed Web of Science ®Google Scholar
• Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837–849.
   PubMed Web of Science ®Google Scholar
• Harvoni (ledipasvir-sofosbuvir) tablets: U.S. prescribing information. Foster City CGS; cited 2015 March. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• German PYJ, West S, Han L, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. May 19-21 2014. Washington, DC. Abstract P_15.
   Google Scholar
• Kirby BMA, Yang C, et al. Metabolism and excretion of ledipasvir (GS-5885) in humans 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. [abstractO_20].
   Google Scholar
• European Association for Study of L. EASL recommendations on treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• German P, Moorehead L, Pang P, et al. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. J Clin Pharmacol. 2014;54:1290–1298.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug; [cited 2015 November 28]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm
   Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(736–43):e1.
   Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.
   PubMed Web of Science ®Google Scholar
• Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049–1054.
   PubMed Web of Science ®Google Scholar
• Wilson E, Kattakuzhy S, Sims Z, et al. Highly successful retreatment with ledipasvir (LDV) and Sofosbuvir (SOF) in HCV GT-1 patients who failed initial short course therapy with combination DAA regimens (NIH SYNERGY Trial). AASLD; 13-15 November 2015, San Francisco, CA. Abstract 92.
   Google Scholar
• Pungpapong S, Michael D, Kymberly D, et al. Multicenter experience using Sofosbuvir/Ledipasvir with or without Ribavirin to treat Hepatitis C Genotype 1 Relapsers after Simeprevir and Sofosbuvir treatment. AASLD. 13-15 November 2015 San Fracisco, CA. Abstract 1038.
   Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.
   PubMed Web of Science ®Google Scholar
• Manns MFX, Samuel D Ledipasvir/Sofosbuvir with Ribavirin is safe and efficacious in decompensated and post-liver transplantation patients with HCV Infection: preliminary results of the SOLAR-2 trial. Presented at: International Liver Congress; April 22-26, 2015; Vienna. Austria. Abstract G02.
   Google Scholar
• Gane EJ, Manns M, McCaughan G, et al. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials. AASLD 13-17 November 2015, San Francesco Abstract 1049.
   Google Scholar
• German PYJ, West S, Han L, et al.: Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. May 19-21, 2014. Washington, DC. Abstract P_15.
   Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–1239.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–13.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(1454–61):e1.
   Google Scholar
• Bourliere M, Bronowicki JP, De Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Wan-Long C, Hassanein T, et al. Sofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with chronic genotype 6 Hepatitis C virus infection: integrated analysis of phase 2 and phase 3 studies. AASLD 13-17 November 2015, San Francisco Abstract 1120.
   Google Scholar
• Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86.
   PubMed Web of Science ®Google Scholar
• Samuel D, Manns M, Forns X, et al. P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: an integrated safety analysis of the solar 1 and solar 2 trials. Annual meeting of the Europen Association for the Study of the Liver (EASL). 22-26 April 2015. Vienna, Austria. 62 S620-S621
   Google Scholar
• Simon TG, Kim AY, Stamm LM, et al. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antivir Ther. 2015. doi:10.3851/IMP2997. [Epub ahead of print].
   Web of Science ®Google Scholar
• Stedman CA, Hyland RH, Ding X, et al. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia Official J World Fed Hemophilia. 2015. doi:10.1111/hae.12791. [Epub ahead of print].
   Google Scholar
• Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725.
   PubMed Web of Science ®Google Scholar
• VIEKIRA PAK [package insert]. North Chicago, IL: AbbVie Inc; 2015.
   Google Scholar
• Simeprevir (OLYSIO ®) full prescribing information. Available from: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
   Google Scholar
• Bernstein DMR, Cohen D, et al. Adherence to prescribed doses of ABT-450/ r/Ombitasvir, Dasabuvir, and Ribavirin in the phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials. Presented at The annual meeting of the American association for the study of the Liver diseases (AASLD). 7-11 November 2014; Boston, MA.
   Google Scholar
• Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13:3351–3357.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected patients with severe renal impairment or end-stage renal disease. AASLD; Nov 13-17 2015;San Francisco, CA. Abstract 1039.
   Google Scholar
• Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61:1793–1797.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 31:2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015; 31:2608–2617.
   Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 31:2618–2628.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee. EASL recommendations on treatment of Hepatitis C 2015. J Hepatol. 2015; 63:199–236.
   Google Scholar